Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin: A ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) Analysis.
作者信息
Lindner Samuel M, Fordyce Christopher B, Hellkamp Anne S, Lokhnygina Yuliya, Piccini Jonathan P, Breithardt Günter, Mahaffey Kenneth W, Singer Daniel E, Hacke Werner, Halperin Jonathan L, Hankey Graeme J, Berkowitz Scott D, Nessel Christopher C, Becker Richard C, Fox Keith A A, Patel Manesh R
机构信息
From Duke Clinical Research Institute, Duke University Medical Center, Durham, NC (S.M.L., C.B.F., A.S.H., Y.L., J.P.P., M.R.P.); Division of Cardiology, University of British Columbia, Vancouver, Canada (C.B.F.); Department of Cardiovascular Medicine, University of Münster, Germany (G.B.); Stanford University School of Medicine, CA (K.W.M.); Massachusetts General Hospital and Harvard Medical School, Boston (D.E.S.); Ruprecht-Karls-University, Heidelberg, Germany (W.H.); Cardiovascular Institute, Mount Sinai Medical Center, NY (J.L.H.); School of Medicine and Pharmacology, The University of Western Australia, Crawley (G.J.H.); Bayer HealthCare Pharmaceuticals, Parsippany, NJ (S.D.B.); Janssen Research and Development LLC, Raritan, NJ (C.C.N.); University of Cincinnati College of Medicine, OH (R.C.B.); and University of Edinburgh and Royal Infirmary of Edinburgh, UK (K.A.A.F.).
出版信息
Circulation. 2017 Mar 7;135(10):1001-1003. doi: 10.1161/CIRCULATIONAHA.116.024666.
Zotero 插件